Notably: BPC-157, KPV, MOTs-C, Emideltide (DSIP), Epitalon, Semax (heptapeptide) and TB-500 are among those expected to be reviewed in July 2026 Other substances, including Cathelicidin LL-37, Dihexa Acetate, PEG-MGF, GHK-Cu and Melanotan II, are under consideration for review by early 2027 Non-injectable GHK-Cu is following a slightly different path, with separate evaluation anticipated before February 2027
PMID:11035391 [8] Hruby VJ, Lu D, Sharma SD, Castrucci AL, Kesterson RA, al-Obeidi FA, Hadley ME, Cone RD
Then, body makeup changes become noticeable
Daily or twice-weekly dosing is unnecessary methionine, inositol, and choline have half-lives that support weekly administration, and more frequent dosing increases homocysteine and trimethylaminuria risk without additional metabolic benefit
Now, I take maintenance doses occasionally to keep my appetite in check
Watch-outs to know : Some scientists are concerned with Epitalon because the peptide interacts with telomeres